Why don't people start with low-dose of dutasteride?
    Finasteride/Dutasteride 7/20/2025

    From the encyclopedia
    Dutasteride →

    Heavy duty finasteride that comes with higher risks

    Finasteride →

    Frontline, gold standard treatment for combatting androgenic alopecia

    At a glance
    In this general discussion post, the primary subjects mentioned are
    💊 Dutasteride (oral) 0.1 to 0.25mg per day or 0.5mg every 3-5 days
    💊 Finasteride (oral) 1mg
    the tone is 😐 neutral.

    Other terms

    The conversation discusses the use of dutasteride and finasteride for hair loss, with a focus on starting with low doses of dutasteride to match the DHT suppression of finasteride. It highlights the longer half-life and potential side effects of dutasteride, as well as the preference for finasteride due to its availability and research backing.
    View this post in the Community →

    Similar Community Posts Join

    5 / 5 results

    Related Research

    6 / 6 results
      Finasteride for Hair Loss: A Review

      research Finasteride for hair loss: a review

      4 citations , July 2021 in “Journal of Dermatological Treatment”
      This meta-analysis reported that finasteride 1 mg/day significantly increased hair count in male androgenetic alopecia compared to placebo, but highlighted persistent sexual side effects and associated depression risk.
      Dutasteride as an Effective Treatment in Androgenetic Alopecia: A Literature Review

      research DUTASTERIDE AS AN EFFECTIVE TREATMENT IN ANDROGENETIC ALOPECIA – A LITERATURE REVIEW

      September 2025 in “International Journal of Innovative Technologies in Social Science”
      This review found that dutasteride is more effective than finasteride in increasing hair count and shaft thickness for androgenetic alopecia in men, with potential for reduced systemic side effects through mesotherapy, although further research is needed on long-term safety and dosage.
      5α-Reductase Inhibitors: Finasteride and Dutasteride in Feminizing Therapy

      research 5α-reductase Inhibitors: Finasteride and Dutasteride in Feminising Therapy

      6 citations , July 2026 in “Zenodo (CERN European Organization for Nuclear Research)”
      This review evaluates the use of 5α-reductase inhibitors in feminising hormone therapy, finding their additive feminising benefits unclear due to their specific action on testosterone conversion, with concerns highlighted regarding limited supporting evidence and safety signals, particularly for psychiatric and sexual effects.